Feb. 19, 2025 – A vaccine for pregnant women that protects babies from respiratory syncytial virus (RSV) appears safe, according to two new studies that give researchers hope for widespread ...

High vaccine uptake shows promise for the prevention of respiratory syncytial virus (RSV) in infants. The rollout of 2 major interventions to prevent severe respiratory syncytial virus (RSV ...

The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study. The phase 3 randomized controlled ...

Due to intrinsic variability and low levels of broadly neutralizing antibodies following vaccination, most vaccine developers are not pursuing the G protein as a component of an RSV vaccine.

Local health boards invited adults aged 75–79, including those turning 75 before July 2025, to come forward for their free RSV vaccine ahead of the winter. By the end of November 2024 ...

PRC vaccine leader AIM Vaccine (06660.HK) announced on February 26 that its self-developed mRNA RSV (Respiratory Syncytial Virus) vaccine has recently received clinical trial approval from the U.S ...